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Abstract
Ceramide kinase (CERK) produces the bioactive lipid ceramide-1-phosphate (C1P) and is a key regulator of cera-
mide and dihydroceramide levels. It is likely that CERK and C1P play a role in inflammatory processes but the cells
involved and the mechanisms used remain to be clarified. In particular, the impact of CERK on T-cell biology has
not been studied so far. Here, we used Cerk
-/- mice backcrossed with DO11.10/RAG1
-/- mice to probe the effect of
CERK ablation on T-cell activation. Levels of interleukin (IL)-2, IL-4, IL-5, IL-13, of tumor necrosis factor (TNF)-a, and
of interferon (INF)-g were recorded following ovalbumin challenge in vivo and using ovalbumin-treated splenocytes
ex- vivo. Absence of CERK led to a significant decrease in the production of IL-4, thus suggesting that CERK may
polarize T cells towards the TH2 cell subtype. However, the importance of CERK to TH2 cell biology will have to be
investigated further because in a model of asthma, which is TH2-cell driven, Cerk
-/- mice responded like wild-type
animals.
Background
Ceramide kinase (CERK), together with sphingosine
kinases (SPHK) 1 and 2, belongs to the diacyglycerol
kinase family of lipid kinases. CERK is the only enzyme
known to produce ceramide-1-phosphate (C1P) [1].
However, studies with CERK deficient (Cerk
-/-)m i c e
have shown that another route for production of C1P
must exist, at least in mammals [2,3]. The best
described signaling properties reported for C1P include,
on the one hand, a positive effect on cell proliferation
and cell survival [4,5] and, on the other hand, the con-
trol of cytosolic phospholipase A2 (cPLA2) activity
[6-9]. Of note, however, neither knocking down the
Cerk gene [3] nor using a CERK inhibitor [10] could
recapitulate these findings, which suggests compensation
by other C1P pools that do not depend on CERK for
their synthesis.
The physiological role of CERK and its relevance to
d i s e a s ei so n l ys t a r t i n gt ob ea d d r e s s e d .U s i n gag e n e
knockdown strategy Igarashi and coworkers have shown
p r e l i m i n a r ye v i d e n c ef o rar o l eo fC E R Ki ne m o t i o n a l
behavior [11]. Based on ex- vivo work with CERK-defi-
cient endothelial cells together with use of the CERK
inhibitor NVP-231 [10] our laboratory has recently pro-
posed a role for CERK in the regulation of angiogenesis
[12]. CERK may also be relevant to immune cell biology.
In fact, neutrophils represent one of the first cell types
where CERK/C1P were described [13-15] and subse-
quently shown to promote phagolysosome formation
[16]. More recently, the study of C1P/CERK in mast
cells has suggested their function in the degranulation
process [17]. Consistently, in a model of passive cuta-
neous anaphylaxis, Cerk
-/- animals were partially pro-
tected [3]. However, Cerk
-/- responded similarly to
control littermates during a model of active cutaneous
anaphylaxis [3]. In fact, work in vitro with CERK-defi-
cient primary bone marrow derived mast cells or with
the NVP-231 inhibitor failed to clarify a putative role of
CERK/C1P in mast cell biology [3,10]. In an antigen-
induced arthritis model, Cerk
-/- mice were not protected,
thus inconsistent with the hypothesis that C1P made by
CERK is key for cPLA2 activation in vivo – parallel
pharmacological inhibition of cPLA2 could indeed dam-
pen disease development [3]. In sharp contrast, absence
of CERK prevented Cerk
-/- animals from mounting an
effective response against a pulmonary insult by
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CERK seems to play a role in inflammation, the overall
picture remains contrasted and no consensus has
emerged yet.
The study reported here was undertaken to examine
T-cell specific responses in the absence of CERK. To
this aim we made use of the established DO11.10
RAG1
-/- background [18-20]. In DO11.10 mice all thy-
mocytes and peripheral T cells express the transgenic
TCR receptor from a T cell hybridoma, DO11.10, that
recognizes chicken ovalbumin (OVA) in the context of
I-A
d class II MHC molecules. Furthermore, in DO11.10/
RAG1
-/- mice, the endogenous TCR a-chains are elimi-
nated, and T cells can only express the transgenic recep-
tor. This model has proven useful for studying T-cell
specific responses. Therefore, we backcrossed Cerk
-/-
mice with DO11.10/RAG1
-/- mice to probe the effect of
CERK ablation on T-cell activation. In parallel, we also
backcrossed Sphk1
-/- and Sphk2
-/- to the same back-
ground for comparison.
Methods
Generation of DO11.10 RAG1
-/- mice strains
Mice deficient in either CERK, SPHK1 or SPHK2 were
backcrossed with DO11.10 RAG1
-/- mice; all strains
were on a Balb/C background. Deficiency for CERK,
SPHK1 or SPHK2 was analyzed by RT-PCR as pre-
viously described [3,21]. For examination of the expres-
sion of the transgenic TCR receptor, blood was taken
from the retro-bulbar complex, erythrocytes were lysed
and T cells were stained with an anti KJ 126- FITC con-
jugated antibody (Caltag) and analyzed by flow cytome-
try (Becton Dickinson Excalibur).
Ovalbumin challenge in vivo
On day 0 and 5, mice were sensitized by intraperitoneal
injections of alum-precipitated ovalbumin (OVA) con-
taining 100 μg OVA (Sigma) absorbed to 2 mg Al(OH)3
(Alu Gel S (2% Al(OH)3, Serva) and diluted with saline
to a volume of 0.2 ml.
Splenocyte isolation, culture and ovalbumin treatment
After immunization with OVA as described above,
spleens were isolated and single splenocyte suspensions
were prepared by lysing erythrocytes with FACS Lysing
Solution (Becton Dickinson). One million cells/well of
splenocytes were seeded in 96 well plates (Becton Dick-
inson), and incubated with 10 μg/ml OVA323-339 peptide
for 3.5 hours in RPMI1640 supplemented with 100 U/
ml penicillin, 100 μg/ml streptomycin sulfate and 10%
FBS. After the incubation, culture supernatant were har-
vested, and kept at -20°C until cytokine measurement.
Cytokine measurements
For parallel determination of cytokines in serum multi-
plex reagents from BioRad were used; analyses were
conducted using a BioPlex 200 System, the BioPlex Pro
reagent kit and human standards group I + II. Cytokine
concentrations in the samples were calculated from cali-
bration curves using the software XL-fit (IDBS Ltd.). IL-
4 levels in culture medium of isolated splenocytes were
measured by enzyme-linked immunosorbent assay
(ELISA), following the manufacturer’s instructions (R&D
Systems).
Asthma model
On days 0 and 5, mice were sensitized by intraperitoneal
injection of alum-precipitated ovalbumin (cf above) and
diluted with saline to a volume of 0.2 ml. On day 0 and
13, 200 μl blood was collected by puncture of the retro-
bulbar plexus under isoflurane anesthesia. Sera were
prepared and stored frozen at -20°C until analyzed for
OVA-specific IgE and IgG1in serum. On day 12, the
animals were challenged with aerosolized OVA (1.0%
wt/vol in PBS) for 60 min, twice. The aerosol was gener-
ated by a “Small Particle Aerosol Generator” (SPAG-2,
Serotherapeutisches Institut) driven by compressed air
at 6 l/min. Under these conditions the median particle
diameter was 0.5 μm. Forty eight hours after the first
aerosol exposure, mice were euthanized with pentobar-
bital (Nembutal 70 μl/mouse i.p.). The trachea was
t r i m m e df r e eo fc o n n e c t i v et i s s u ea n dac a n n u l aw a s
inserted. The lungs were lavaged with 3 × 1 ml saline at
37°C instilled through the tracheal cannula by a syringe.
After five gentle massages of the thorax, approximately
3 × 0.7 ml brochoalveolar lavage fluid (BAL) was
retrieved from the lungs and collected in an ice-cold
plastic tube. The cells were counted using a Sysmex
KX-21 cell counter (TOA). Differential cell counts were
performed on cytocentrifuge preparations (Labofuge A;
Heraeus) and stained with May-Grunwald/Giemsa. Dif-
ferential cell counts were determined from at least 500
cells, and calculated per ml BAL fluid. Serum OVA-spe-
cific IgE and IgG1 levels were determined in mouse sera
by ELISA. For the determination of OVA-specific IgE,
100 μl of rat anti mouse IgE heavy chain antibody (LO-
ME-3, Serotec) at a concentration of 5 μg/ml bicarbo-
nate buffer, pH 9.6, were added to each well of ELISA
microtiter plates (cert. Maxisorp, Nunc). The plates
were incubated at 4°C for 3 hrs then washed three times
with wash buffer + 1% FCS. One hundred-μlo fO V A
reference serum (100 relativ eu n i t s / m l )o rt e s ts e r a
diluted in wash buffer + 1% FCS in threefold steps were
distributed into each well and incubated for 2 hrs at
room temperature. Washing was repeated three times
before 100 μl of biotinylated OVA (1:6000) in wash buf-
fer + 1% FCS were distributed into each well and incu-
bated over night at 4°C. After washing three times, 100
μl horseradish peroxidase avidin D (1:3000, Vector Labs)
was added for 2 hrs at room temperature. Plates were
washed three times with wash buffer followed three
times with substrate buffer before adding 100 μlo ft h e
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phosphate citrate buffer containing 0.003% H2O2)i n t o
each well and incubating them for fifteen minutes at
room temperature. The reaction was stopped with 50 μl
4N H2SO4 a n dt h eO D4 9 2n mr e a du s i n gam i c r o t i t e r
spectrophotometer (TECAN Spectra). The ODs of the
serum samples were related to the standard curve and
the amount of OVA-specific IgE were calculated. For
determination of OVA-specific IgG1, 100 μlo fO V Aa t
a concentration of 2 μg/ml bicarbonate buffer, pH 9.6,
were added to each well of ELISA microtiter plates
(cert. Maxisorp, Nunc). The plates were incubated at 37°
C for 2 hrs and stored until use at 4°C. Then the plates
were washed three times with wash buffer. One hun-
dred-μl of OVA reference standard serum or test sera
diluted in PBS + 1% FCS in threefold steps were distrib-
uted into each well and incubated for 2 hrs at 37°C.
Washing was repeated three times before 100 μlo fb i o -
tinylated anti-mouse IgG1 (The Binding Site, diluted
1:10,000) were added to each well and incubated for 60
min at 37°C. After repeated washings, 100 μlo fh o r s e -
radish peroxidase (Vector Lab.) was added for 60 min at
37°C, and then washed three times with wash buffer.
The assay was developed using the same procedure as
for OVA-specific IgE measurement. PGE2 in BALF was
measured by ELISA (R&D Systems) according to the
manufacturer’s instructions.
Results
Reduced IL-4 levels in Cerk
-/- DO11.10/RAG 1
-/- mice
challenged with ovalbumin
T cell activation triggers signaling mechanisms that
induce the production and secretion of cytokines. Func-
tionally, cytokines have been classified as being either
pro-inflammatory (TH1 type) or anti-inflammatory (TH2
type) depending on the final balance of their effects on
the immune system. For analysis, we selected a panel of
cytokines belonging to these two categories, namely IL-
2, TNF-a, INF-g (TH1) and IL-4, IL-13 and IL-5 (TH2).
The four strains (wild-type (WT), Cerk
-/-, Sphk1
-/- and
Sphk2
-/-), all in the DO11.10 RAG1
-/- background, were
challenged with ovalbumin. Blood samples were col-
lected at 2 h and 4 h post challenge and the levels of
the above-mentioned cytokines in the serum was mea-
sured using multiplex analysis (Fig. 1). IL-4 levels in the
serum were reduced by 70% in Cerk
-/- compared to WT
(p = 0.01) and compared to both SPHK-deficient ani-
mals. There was also a clear trend towards reduction of
secreted IL-13 in Cerk
-/- animals (- 45%; p = 0.10 vs
WT), which was observed neither with Sphk1
-/- nor
Figure 1 Cytokine release upon OVA challenge in DO11.10 RAG1
-/- mouse lines. Cerk
-/-, Sphk1
-/- and Sphk2
-/- and WT mice all in the
genetic background DO11.10 RAG1
-/-, were challenged with OVA as described in the Experimental section. Blood samples were collected after 2
h and 4 h for cytokine measurement and serum was prepared. Serum cytokine levels shown are the mean ± SD of the 2 h together with the 4
h measurements expressed as a percentage of WT levels, from 3 independent experiments with a total of 24 animals per group.
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-/- animals. A trend for reduction of IL-5
levels (-45%; p = 0.07 in Cerk
-/- vs WT) was seen for all
3 knock-out strains. Levels for all other measured cyto-
kines were not significantly different from WT levels.
To confirm the data obtained in vivo, we measured
IL-4 secretion ex- vivo, from CERK-deficient DO11.10/
RAG 1
-/- splenocytes. After 3.5 h of ovalbumin peptide
challenge in culture, the levels of IL-4 secreted by
Cerk
-/- cells was reduced by 30% (p = 0.04) compared to
WT cells (Fig. 2).
Cerk
-/- mice are not protected in an ovalbumin-induced
asthma model
IL-4, IL-5 and IL-13 are key cytokines for adaptive
immunity, produced by CD4
+ Tc e l l so ft h eT H2t y p e .
The overall reduced production of these cytokines in
Cerk
-/- DO11.10/RAG1
-/- mice therefore suggested a pos-
sible contribution of CERK to TH2 cell biology. In addi-
tion, because IL-4 and IL-13 are important regulators of
immediate hypersensitivity reactions by inducing B cell
immunoglobulin (Ig) heavy chain class switching to the
IgE isotype, the strong depletion of IL-4 levels in absence
of CERK might have broader implications. Therefore, we
submitted Cerk
-/- mice to an ovalbumin-induced asthma
model, where cytokines such as IL-4 and IL-13 are play-
ing key roles. We measured leukocyte infiltration, immu-
noglobulin levels in the serum as well as inflammatory
mediator release. When assessed 2 days after the final
ovalbumin aerosol challenge, the numbers of eosinophils,
macrophages, lymphocytes and neutrophils, harvested
from the bronchoalveolar lavage fluid, were indistin-
guishable in WT and Cerk
-/- animals (Fig. 3A). Similar
observations were made for IgG1 and IgE levels (Fig. 3B)
and for prostaglandin (PG) E2 levels (Fig. 3C).
Discussion
The results obtained with Cerk
-/- compared to Sphk1
-/-
and Sphk2
-/-, in the DO11.10/RAG1
-/- genetic back-
ground, revealed that IL-4 production and/or release,
after T-cell activation, is dependent on CERK (Fig.1 and
Fig. 2). Furthermore, even if this did not reach statistical
significance, the same experiments also revealed that IL-
13 and IL-5 levels are reduced in absence of CERK (Fig.
1). Altogether, this suggested that CERK may play a role
in TH2 cytokine production. Remarkably however,
Cerk
-/- animals (in the normal Balb/C background) were
not protected in an asthma model where TH2 cells are
considered to be a driving force (Fig. 3). It is possible
that reduction of IL-4 levels in absence of CERK has
not been sufficient to limit the immune response;
equally possible might be the mechanistic redundancy
between cytokines (e.g. IL-4 and IL-13; levels of the lat-
ter are only partially reduced in absence of CERK; Fig.
1). An alternative explanation might be differential com-
pensation in a background of C1P reduction (due to
absence of CERK) in the two models. Readouts in
DO11.10 were taken after 2 to 4 h whereas analysis in
the asthma model took place after 48 h; compensatory
C1P synthesis (by unknown mechanisms, cf ref. [2])
might be limiting only for short period of times. Alto-
gether, despite a clear cut influence on IL-4 levels, to
what extent CERK may participate in TH2c e l lb i o l o g y
remains elusive. Interestingly, however, infectious
reagents such as LPS or the TH1c y t o k i n eI N F - g can
inhibit CERK at mRNA levels in primary macrophages
(P. Rovina and F. Bornancin, unpublished data) thus
supporting the notion that CERK activity may be posi-
tively linked to the TH2 rather than to the TH1p h e n o -
type (Fig. 4).
Basal levels of PGE2 in BAL fluid were significantly
reduced in control Cerk
-/- compared to control WT
mice (Fig. 3C). In fact, this observation provides first in
vivo support to the hypothesis that CERK signals to
cPLA2, which has already been well validated in vitro
[6-9]. It also indicates that the contribution of CERK/
C1P to cPLA2 function might be best evidenced when
cPLA2 is sub-optimally activated. Other mechanisms
may prevail under developing acute or chronic inflam-
mation e.g. during the asthma model presented here.
In addition to the asthma model of the present work,
other disease models of the lung were tested with
Cerk
-/- mice. A smoke-induced chronic obstruction
model, where increased sensitivity in the absence of
Figure 2 IL-4 release in OVA challenged isolated splenocytes.
Splenocytes from DO11.10 RAG1
-/- and from Cerk
-/- DO11.10 RAG1
-/-
mice were isolated following ovalbumin challenge in vivo as
described in the Experimental section. Cultured splenocytes were
then incubated with 10 μg/ml OVA323-339 peptide or with saline
(control) for 3.5 hours and IL-4 levels were measured in cell culture
supernatant. The data shown represent the mean ± SD of
measurements obtained from 8 animals (OVA-treated) and 2
animals (controls). In this experiment it was not possible to match
the age of the animal population optimally: DO11.10 RAG1
-/- were 8
weeks of age at start of the experiment whereas Cerk
-/- DO11.10
RAG1
-/- mice were between 11 and 14 weeks of age.
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Figure 4 CERK and TH1/TH2 cytokines. This schematic representation summarizes the current knowledge of the interplay between CERK and
cytokines. The TH1 cytokine INF-g as well as LPS can repress CERK at transcriptional level in primary mouse macrophages which indicates that a
TH1 response may require initial down-regulation of CERK; this can be reversed by corticosteroids. The present work provides evidence that TH2
cytokine production, IL-4 in particular, are dependent on CERK. Altogether, this suggests that CERK may polarize immune responses towards the
TH2 type.
Figure 3 Asthma model. Cerk
-/- and WT mice were exposed to OVA-aerosol as described in the Experimental section. BAL fluid and blood were
collected at 48 hours after OVA challenge. The number of infiltrated inflammatory cells (A), OVA-specific IgG1 and IgE in serum (B) and PGE2 in
BAL fluid (C) are represented as the mean ± SEM of 8 animals per group.
Niwa et al. Lipids in Health and Disease 2010, 9:1
http://www.lipidworld.com/content/9/1/1
Page 5 of 6CERK may be expected because of up-regulated cera-
mide levels [3], failed to reveal significant differences
between Cerk
-/- and WT control littermates (data not
shown). A bleomycin-induced fibrosis model, where IL-
13 is key, also did not show differences between Cerk
-/-
and WT control littermates (data not shown). In fact,
the sole lung pathology where we observed a statistically
different behavior in Cerk
-/- compared with WT is an
infection model with S. pneumoniae, as already reported
[3]. During this fulminant infection, absence of CERK
led to drastic worsening of the disease resulting in early
mortality. We initially speculated on increased ceramide
levels in absence of CERK leading to premature neutro-
phil apoptosis and inefficient first line defense [3].
Should the T cells be polarized by CERK towards the
TH2 type (Fig. 4), the opposite hypothesis could also be
considered, i.e. hyperactivation of host defenses in
Cerk
-/- mice might have led to poor control of the infec-
tion. In fact, the dynamic (as opposed to “established” i.
e. in KO animals) down-regulation of CERK might
represent a negative feedback mechanism. Clearly,
further experiments are required to understand the con-
tribution of CERK to inflammation. In light of available
data including the results of the present study, CERK
may play a ‘fine tuning’ role in inflammatory processes.
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